180 related articles for article (PubMed ID: 1512250)
1. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
Reilly CF; Hutzelmann JE
J Biol Chem; 1992 Aug; 267(24):17128-35. PubMed ID: 1512250
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
[TBL] [Abstract][Full Text] [Related]
3. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
5. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
[TBL] [Abstract][Full Text] [Related]
6. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
Reilly CF; Fujita T; Mayer EJ; Siegfried ME
Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
[TBL] [Abstract][Full Text] [Related]
7. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
Masson C; Angles-Cano E
Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
[TBL] [Abstract][Full Text] [Related]
9. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
10. The activation of plasminogen by T-PA-PAI-1 complex in the absence of fibrin.
Takada Y; Takada A
Thromb Res; 1991 Jul; 63(1):169-77. PubMed ID: 1835180
[TBL] [Abstract][Full Text] [Related]
11. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
Stringer HA; Pannekoek H
J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
[TBL] [Abstract][Full Text] [Related]
12. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Bu G; Morton PA; Schwartz AL
J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
14. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
[TBL] [Abstract][Full Text] [Related]
15. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
[TBL] [Abstract][Full Text] [Related]
17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
18. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro.
Ramsby ML; Kreutzer DL
Invest Ophthalmol Vis Sci; 1993 Oct; 34(11):3207-19. PubMed ID: 7691778
[TBL] [Abstract][Full Text] [Related]
19. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
20. The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1.
Gaussem P; Anglés-Cano E
Biochim Biophys Acta; 1991 Sep; 1079(3):321-9. PubMed ID: 1911857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
